Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
NURO's Cash to Debt is ranked higher than
92% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. NURO: No Debt )
NURO' s 10-Year Cash to Debt Range
Min: 0.63   Max: No Debt
Current: No Debt

Equity to Asset 0.46
NURO's Equity to Asset is ranked higher than
60% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. NURO: 0.46 )
NURO' s 10-Year Equity to Asset Range
Min: -6.3   Max: 0.91
Current: 0.46

-6.3
0.91
Interest Coverage No Debt
NURO's Interest Coverage is ranked higher than
86% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. NURO: No Debt )
NURO' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: -15.19
M-Score: -3.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -140.57
NURO's Operating margin (%) is ranked lower than
52% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. NURO: -140.57 )
NURO' s 10-Year Operating margin (%) Range
Min: -261.35   Max: 5.18
Current: -140.57

-261.35
5.18
Net-margin (%) -155.50
NURO's Net-margin (%) is ranked lower than
51% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.64 vs. NURO: -155.50 )
NURO' s 10-Year Net-margin (%) Range
Min: -251.65   Max: 7.72
Current: -155.5

-251.65
7.72
ROE (%) -130.28
NURO's ROE (%) is ranked lower than
52% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. NURO: -130.28 )
NURO' s 10-Year ROE (%) Range
Min: -100.64   Max: 10.91
Current: -130.28

-100.64
10.91
ROA (%) -72.70
NURO's ROA (%) is ranked lower than
52% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. NURO: -72.70 )
NURO' s 10-Year ROA (%) Range
Min: -135.91   Max: 8.66
Current: -72.7

-135.91
8.66
ROC (Joel Greenblatt) (%) -3831.68
NURO's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. NURO: -3831.68 )
NURO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2814.15   Max: 124.95
Current: -3831.68

-2814.15
124.95
Revenue Growth (3Y)(%) -56.10
NURO's Revenue Growth (3Y)(%) is ranked lower than
52% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. NURO: -56.10 )
NURO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -58.7   Max: 4.3
Current: -56.1

-58.7
4.3
EBITDA Growth (3Y)(%) -54.20
NURO's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. NURO: -54.20 )
NURO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -59.4   Max: 8.8
Current: -54.2

-59.4
8.8
EPS Growth (3Y)(%) -52.70
NURO's EPS Growth (3Y)(%) is ranked lower than
51% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. NURO: -52.70 )
NURO' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.7   Max: 3.4
Current: -52.7

-52.7
3.4
» NURO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

NURO Guru Trades in Q2 2013

Jim Simons 91,325 sh (+8.3%)
» More
Q3 2013

NURO Guru Trades in Q3 2013

Jim Simons 87,925 sh (-3.72%)
» More
Q4 2013

NURO Guru Trades in Q4 2013

Jim Simons 78,950 sh (-10.21%)
» More
Q1 2014

NURO Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NURO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.30
NURO's P/B is ranked higher than
79% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.52 vs. NURO: 2.30 )
NURO' s 10-Year P/B Range
Min: 0.27   Max: 13.18
Current: 2.3

0.27
13.18
P/S 1.90
NURO's P/S is ranked higher than
80% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. NURO: 1.90 )
NURO' s 10-Year P/S Range
Min: 0.2   Max: 15.14
Current: 1.9

0.2
15.14
EV-to-EBIT -0.32
NURO's EV-to-EBIT is ranked higher than
51% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.95 vs. NURO: -0.32 )
NURO' s 10-Year EV-to-EBIT Range
Min: -2675.3   Max: 408.7
Current: -0.32

-2675.3
408.7
Current Ratio 5.23
NURO's Current Ratio is ranked higher than
88% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. NURO: 5.23 )
NURO' s 10-Year Current Ratio Range
Min: 2.29   Max: 13.01
Current: 5.23

2.29
13.01
Quick Ratio 4.99
NURO's Quick Ratio is ranked higher than
91% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. NURO: 4.99 )
NURO' s 10-Year Quick Ratio Range
Min: 1.79   Max: 12.52
Current: 4.99

1.79
12.52

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.30
NURO's Price/Net Cash is ranked higher than
97% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. NURO: 3.30 )
NURO' s 10-Year Price/Net Cash Range
Min: 0.68   Max: 19.26
Current: 3.3

0.68
19.26
Price/Net Current Asset Value 2.80
NURO's Price/Net Current Asset Value is ranked higher than
96% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. NURO: 2.80 )
NURO' s 10-Year Price/Net Current Asset Value Range
Min: 0.56   Max: 15.74
Current: 2.8

0.56
15.74
Price/Tangible Book 2.30
NURO's Price/Tangible Book is ranked higher than
84% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.62 vs. NURO: 2.30 )
NURO' s 10-Year Price/Tangible Book Range
Min: 0.44   Max: 13.02
Current: 2.3

0.44
13.02
Price/Median PS Value 1.70
NURO's Price/Median PS Value is ranked higher than
58% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. NURO: 1.70 )
NURO' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 11.78
Current: 1.7

0.32
11.78
Earnings Yield (Greenblatt) -312.50
NURO's Earnings Yield (Greenblatt) is ranked lower than
57% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. NURO: -312.50 )
NURO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -312.5   Max: 3374.7
Current: -312.5

-312.5
3374.7

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:NLZB.Germany,
NeuroMetrix Inc was incorporated in Delaware in June 1996. The Company is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company develops and markets neurodiagnostic systems which consist of a medical device plus single patient-use biosensors or electrodes. Other accessories are also offered to its customers. The Company's product portfolio includes NC-stat DPN check for Diabetes Diagnostics; Sensus for Pain Management and Advance NCS/EMG System for Orthopedics & Neurology. NC-stat DPNCheck is a fast, accurate, and quantitative nerve conduction test that is used to evaluate systemic neuropathies such as DPN. It is designed to be used by primary care physicians, endocrinologists, podiatrists and other clinicians at the point-of-care to objectively detect, stage, and monitor DPN. The device measures nerve conduction velocity and response amplitude of the sural nerve, a nerve in the lower leg and ankle. These parameters are recognized as sensitive and specific biomarkers of DPN. The Company also markets a medical device, which has been cleared by the FDA and which is used for the assessment of neuropathies such as carpal tunnel syndrome, diabetes, and sciatica. Its ADVANCE NCS/EMG System, or the ADVANCE System, which is a part of its legacy neurodiagnostics business, is a comprehensive platform for the performance of traditional nerve conduction studies and invasive electromyography procedures. Its ADVANCE System is comprised of; various types of electrodes and needles, its ADVANCE device and related modules, and a communication hub that enables the physician's office to network their device to its servers for data archiving, report generation and other network services. The Company competes with CareFusion Corporation, Cadwell Laboratories, Inc., and Natus Medical Incorporated. The Company's products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the regulations promulgated thereunder, as well as by other regulatory bodies in the United States and abroad.
» More Articles for NURO

Headlines

Articles On GuruFocus.com
NeuroMetrix Inc. (NURO) CEO Shai Gozani buys 200,000 Shares Nov 18 2010 
NeuroMetrix Inc. Reports Operating Results (10-Q) Nov 09 2010 
NeuroMetrix Inc. Reports Operating Results (10-Q) Aug 10 2010 
NeuroMetrix Inc. Reports Operating Results (10-Q) May 14 2010 
NeuroMetrix, Inc. Announces Second Quarter 2009 Financial Results Aug 05 2009 
NeuroMetrix Inc. (NURO) CEO Shai Gozani buys 100,000 Shares Mar 03 2009 
NeuroMetrix, Inc. Reports Total Revenues of $7.2 Million for the Fourth Quarter of 2008 Feb 10 2009 
Nucor Invites You to Join Its Fourth Quarter and Year End of 2008 Conference Call on the Web Jan 02 2009 
Nucor Announces One-Hundred Forty-Third (143rd) Consecutive Cash Dividend Dec 09 2008 

More From Other Websites
NeuroMetrix Selected to Showcase Quell™ Wearable Pain Relief Technology at 2015 CES Unveiled Dec 16 2014
NeuroMetrix Selected to Showcase Quell™ Wearable Pain Relief Technology at 2015 CES Unveiled Dec 16 2014
NeuroMetrix Expands Intellectual Property for Wearable Pain Relief Technology Dec 10 2014
NeuroMetrix Expands Intellectual Property for Wearable Pain Relief Technology Dec 10 2014
NeuroMetrix to Participate in the Benchmark Micro Cap Discovery Conference Dec 08 2014
NeuroMetrix to Unveil Revolutionary Wearable Pain Relief Device at 2015 International Consumer... Nov 19 2014
NeuroMetrix to Unveil Revolutionary Wearable Pain Relief Device at 2015 International Consumer... Nov 19 2014
10-Q for NeuroMetrix, Inc. Oct 30 2014
NeuroMetrix Reports Third Quarter 2014 Financial Results and Business Highlights Oct 28 2014
NeuroMetrix Reports Third Quarter 2014 Financial Results and Business Highlights Oct 28 2014
NeuroMetrix, Inc. Announces Date for 2014 Third Quarter Financial Results Conference Call Oct 21 2014
NeuroMetrix, Inc. Announces Date for 2014 Third Quarter Financial Results Conference Call Oct 21 2014
NeuroMetrix Reports Publication of Study Demonstrating that DPNCheck is Effective at Detecting... Sep 25 2014
NeuroMetrix CEO to Present at 29th Annual Meeting of Japan Society of Diabetic Complications Sep 23 2014
NeuroMetrix CEO to Present at 29th Annual Meeting of Japan Society of Diabetic Complications Sep 23 2014
NeuroMetrix Names Senior Executive to Lead Consumer Healthcare Initiative Frank McGillin - SVP and... Sep 03 2014
NeuroMetrix to Present at Rodman & Renshaw Annual Global Investment Conference Sep 02 2014
NeuroMetrix Reports Second Quarter 2014 Financial Results and Business Highlights Jul 24 2014
NeuroMetrix Marks 10th Year Anniversary of Listing on NASDAQ Jul 22 2014
NeuroMetrix, Inc. Announces Date for 2014 Second Quarter Financial Results Conference Call Jul 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK